Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Matthew Munda

Nurse Practitioner, Family Oklahoma City, OK Nurse Practitioner

NPI 1114300316 CMS profile 10690412

13921 N Meridian Ave Ste 100, Oklahoma City, OK 73134

Open in the dashboard

General payments

$8,236

528 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Munda of Oklahoma City, OK is reported in the CMS Open Payments database as having received $8,236 across 528 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $981 49
2024 General $1,683 100
2023 General $1,856 126
2022 General $1,606 99
2021 General $2,111 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Munda
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Matthew Munda were reported at $981. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Matthew Munda Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,111 $124 $35–$379 $132
2022 $1,606 $141 $44–$430 $149
2023 $1,856 $154 $49–$476 $160
2024 $1,683 $165 $51–$504 $164
2025 $981 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,316 70 payments
  2. Collegium Pharmaceutical, Inc. $755 75 payments
  3. Forte Bio-Pharma LLC $743 48 payments
  4. Lundbeck LLC $582 31 payments
  5. AbbVie, Inc. $478 31 payments
  6. Teva Pharmaceuticals USA, Inc. $409 20 payments
  7. Pfizer Inc. $297 20 payments
  8. Medtronic, Inc. $262 15 payments
  9. Merck Sharp & Dohme Corporation $232 15 payments
  10. Amgen Inc. $222 13 payments
  11. Other $2,942 190 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,236 528 payments
Products named General payments · program years 2021–2025
  1. RELISTOR $1,273 68 payments
  2. PROLATE Pain $743 48 payments
  3. PROLATE Pain $743 48 payments
  4. PROLATE Pain $743 48 payments
  5. NALOCET $743 48 payments
  6. PROLATE Pain $625 41 payments
  7. BELBUCA $575 60 payments
  8. AJOVY $409 20 payments
  9. VYEPTI $361 20 payments
  10. Qutenza $351 23 payments
  11. Other $6,036 391 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$203,757

Of which drugs: $28

Medicare patients

254

Average age 69

Services billed

3,345

146 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 45%
Depression 41%
Ischemic heart disease 37%
Chronic kidney disease 28%
COPD 28%
Heart failure 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $246
$246 — —
PROLATE
  • Forte Bio-Pharma LLC $207
$207 — —
AJOVY
  • Teva Pharmaceuticals USA, Inc. $149
$149 — —
VYEPTI
  • Lundbeck LLC $145
$145 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $135
$135 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

528 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record